This removal was dependent on the Fcy receptors present on the macrophages and Fc region of the antibodies, suggesting that engineering the Fc region of anti-PD-1 treatments could increase the time of antibody engagement with cancer-specific CD8 T cells (94). Here, CD8A is linked to cancer.